This Cell Biology Core has major resources available that are provided to the program project investigators, including melanocytes, keratinocytes, fibroblasts, endothelial cells, bone marrow-derived mesenchymal stem cells, melanoma cells, monoclonal antibodies to melanoma-associated antigens, adenoviral and lentiviral vectors for growth factors, adhesion molecules, and oncogenes. Three-dimensional cultures of normal human skin (skin equivalents, organotypic cultures of skin) with a 'dermis' of fibroblasts embedded in collagen and an 'epidermis' of melanocytes/melanoma cells and keratinocytes are generated and provided to the program investigators. This three-dimensional model is superior to two- dimensional culture because it mimics the in vivo context for the melanocytes/melanoma cells. For screening studies, the Core is providing a spheroid culture model that allows investigations on melanoma cells intimately interacting with stromal cells. The Core provides to program members orthotopic in vivo models of melanoma growth. Due to the different architectures between mouse and human skin, melanomas, including xenografted cells, cannot be grown in the natural murine skin environment. Instead, the Core will first graft human skin onto immunodeficient mice. When the skin has healed, we will inject human melanoma cells intradermally, where growth and invasion occurs in the same way as in patients' lesions. The Core is also providing the subcutaneous melanoma growth model for standard experiments. Besides providing resources to the other projects, the Core will test compounds developed in Projects 3 and 4 and initially selected in Project 1. The responsibility of the Core is in testing expanded number of cell lines, in quality control testing of compounds through the different biological assays and through Western blotting. The Core also trains investigators of the Program in all tumor biological assays. Overall, this Core will provide efficient and high quality service to all interested laboratories within this Program Project.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA114046-05
Application #
8378457
Study Section
Special Emphasis Panel (ZCA1-GRB-P)
Project Start
Project End
2013-08-31
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
5
Fiscal Year
2012
Total Cost
$177,783
Indirect Cost
$102,121
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Kaur, Amanpreet; Webster, Marie R; Marchbank, Katie et al. (2016) sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature 532:250-4
Budina-Kolomets, Anna; Webster, Marie R; Leu, Julia I-Ju et al. (2016) HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. Cancer Res 76:2720-30
Lu, Hezhe; Liu, Shujing; Zhang, Gao et al. (2016) Oncogenic BRAF-Mediated Melanoma Cell Invasion. Cell Rep 15:2012-24
Amaravadi, Ravi; Kimmelman, Alec C; White, Eileen (2016) Recent insights into the function of autophagy in cancer. Genes Dev 30:1913-30
Krepler, Clemens; Xiao, Min; Samanta, Minu et al. (2016) Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma. Oncotarget :
Grasso, Michael; Estrada, Michelle A; Ventocilla, Christian et al. (2016) Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAF(V600E) Conformation. ACS Chem Biol 11:2876-2888
Shannan, Batool; Chen, Quan; Watters, Andrea et al. (2016) Enhancing the evaluation of PI3K inhibitors through 3D melanoma models. Pigment Cell Melanoma Res 29:317-28
Jennis, Matthew; Kung, Che-Pei; Basu, Subhasree et al. (2016) An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev 30:918-30
Chatwichien, Jaruwan; Basu, Subhasree; Budina-Kolomets, Anna et al. (2016) PUMA-dependent apoptosis in NSCLC cancer cells by a dimeric β-carboline. Bioorg Med Chem Lett 26:4884-4887
Krepler, Clemens; Xiao, Min; Sproesser, Katrin et al. (2016) Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clin Cancer Res 22:1592-602

Showing the most recent 10 out of 87 publications